On Friday, General Electric Company (NYSE:GE)’s shares declined -2.03% to $24.83.
GE Aviation will create a turboprop engine development, test and production operation in Europe. This will represent an investment surpassing $400 million and ultimately support 500 – 1,000 jobs.
The turboprop industry is highly global and comprised of many small aircraft operators. Among the factors driving GE Aviation to pursue the new operation in Europe is the need to support these and other international customers with financing through government-sponsored Export Credit Agencies (ECAs).
GE is presently bidding on $11 billion of projects that require export financing. The U.S. remains the only major economy in the world without an Export Bank. Since the U.S. Export Import Bank (Ex-Im) authorization expired July 1, GE has commenced talks with several foreign ECAs to secure financing for its customers.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment. Its Oil and Gas segment provides surface and subsea drilling and production systems, equipment for floating production platforms, compressors, turbines, turboexpanders, reactors, industrial power generation, and auxiliary equipment.
Bristol-Myers Squibb Co (NYSE:BMY)’s shares gained 3.42% to $64.32.
Bristol-Myers Squibb Company (BMY) declared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo for the potential indication of advanced or metastatic renal cell carcinoma (RCC). The Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines with early signals of potential clinical benefit in serious diseases to assist ensure patients have access to new therapies as soon as possible.
This designation is based on results of CheckMate -025, a Phase 3 study that evaluated the survival of patients with formerly treated advanced or metastatic clear-cell RCC as compared to everolimus, a current standard of care for patients with formerly treated kidney cancer. The trial was stopped early in July 2015 because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its primary endpoint of overall survival, demonstrating superior overall survival in patients receiving Opdivo contrast to the control arm. Bristol-Myers Squibb will be presenting further data from this study at the forthcoming 2015 European Cancer Congress (ECC), and looks forward to submitting these data to regulatory authorities this year.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
At the end of Friday’s trade, AES Corp (NYSE:AES)‘s shares dipped -2.10% to $10.94.
The AES Corporation (AES) was named to the Dow Jones Sustainability Index (DJSI) for North America for the second year in a row.
The DJSI is based on the Corporate Sustainability Assessment conducted by RobecoSAM. The annual assessment determines which companies are better equipped to respond to emerging opportunities and risks resulting from global sustainability trends.
For the first time this year, AES’ partner in Chile, AES Gener, take part in RobecoSAM’s annual Corporate Sustainability Assessment. AES Gener received the highest rating among all electric utilities for the Environmental Policy/Administration System category.
The AES Corporation operates as a diversified power generation and utility company. It owns and/or operates power plants to generate and sell power to customers, such as utilities, industrial users, and other intermediaries.
Boeing Co (NYSE:BA), ended its Friday’s trading session with -0.97% loss, and closed at $136.12.
Boeing [NYSE: BA] declared that 747 fuselage panels will be built at its Macon, Georgia facility starting in 2018.
Boeing will take over the work from Triumph Aerostructures – Vought Aircraft Division, a wholly owned partner of Triumph Group, Inc., with the Macon site providing assembled fuselage panels to Boeing’s 747 final assembly line in Everett, Washington. Boeing and Triumph Aerostructures have worked together to ensure a smooth transition for the 747 supply chain.
Boeing and Triumph Aerostructures have worked together for many months to ensure a smooth transition for the 747 supply chain. As part of this detailed process, the Boeing team selected the Boeing Defense, Space & Security Macon facility for 747 fuselage panel work.
Defense work presently performed at the Macon site comprises replacement center wing sections for the A-10 Thunderbolt II, in addition to sub-assemblies for the CH-47 Chinook helicopter. Fuselage panels for the C-17 Globemaster transport airplane were also produced at the site until earlier this year.
The Boeing Company, together with its auxiliaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
